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Abstract
Background—Hepatitis B virus (HBV) is highly endemic in Cambodia with an estimated pre-
vaccine hepatitis B surface antigen (HBsAg) prevalence of 9%. By 2005, a hepatitis B vaccination 
program was implemented to decrease infection rates in children. We conducted a serosurvey to 
evaluate the impact of the vaccination program in 2011.
Methods—A cross-sectional two-stage cluster survey was conducted to estimate HBsAg 
prevalence among children born from 2006 to 2007 in three provinces: Phnom Penh (urban), 
Kratie (rural), and Ratanakiri (remote). Demographic data, as well as written or oral vaccination 
history were collected. Children were tested for HBsAg. Factors associated with undervaccination 
and HBsAg positivity were modeled.
Results—Coverage of timely hepatitis B vaccine birth dose (administered at ≤24 hours) was 
55% in Phnom Penh, 36% in Kratie, and 22% in Ratanakiri. Coverage with ≥3 hepatitis B vaccine 
doses (HepB3) was 91% in Phnom Penh, 82% in Kratie, and 64% in Ratanakiri. When compared 
with children who were born in health facilities with a skilled birth attendant (SBA), children born 
at home without a SBA were more likely not to have received a timely BD (adjusted relative risk 
[aRR]=1.94; 95% CI=1.75–2.15) as were children born at home with an SBA (aRR=1.54; 95% 
CI=1.32–1.80). The proportion of children who tested positive for HBsAg was 0.33% in Phnom 
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Penh, 1.41% in Kratie, and 3.45% in Ratanakiri. In all three provinces, children who received their 
first dose after seven days of life and children who never received hepatitis B vaccine had the 
highest HBsAg prevalence.
Conclusions—Progress has been made in Cambodia in decreasing the burden of chronic HBV 
infection among children. Improvements in vaccination coverage will further decrease the burden 
disease.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a global public health problem that affects an 
estimated 240 million people, with the greatest burden of disease among Asians, most of 
whom acquire the infection from perinatal or horizontal transmission occurring during the 
first five years of life [1, 2]. Cambodia is considered highly endemic for chronic HBV 
infection, with an estimate by the World Health Organization (WHO) Regional Office for 
the Western Pacific of 9% hepatitis B surface antigen (HBsAg) seroprevalence in the 
general population [3], ranging from 7.7%–13% in various subpopulations of adults based 
on convenience sample data [4–9].
In response to the large burden of disease in Cambodia, the government introduced hepatitis 
B vaccine for all infants in a geographically phased manner starting in 2001, with a 
nationwide program in place by 2005. Since 2005, the schedule has been a birth dose (BD) 
within 24 hours of birth, and doses at 6, 10, and 14 weeks of age.
National BD and 3-dose hepatitis B vaccination coverage (HepB3) has been rising yearly 
since introduction from 25% in 2007 to 68% in 2011 for birth dose coverage and from 82% 
in 2006 to 94% in 2011 for HepB3 coverage [10]; however, coverage varied by province 
from 39%–97% for BD and 71%–159% for HepB3 in 2011 (unpublished official Ministry of 
Health immunization coverage data 2011, Figure 1). The range in provincial HepB3 
coverage signifies variable access to routine immunization services, while BD coverage 
variability is largely attributed to access to health facilities and/or skilled birth attendants 
(SBAs) during delivery, with persons in urban areas having greater access to both. In 2010, 
54% of all deliveries were in health facilities with provincial variation of 21%–93%; 
factoring in SBAs providing home care, 71% of deliveries were attended by an SBA, with 
provincial variation of 28%–99% [11]. Difficulties in knowing the true number of children 
eligible for vaccination also accounts for some of the variability in BD and HepB3 coverage 
by province, including coverage exceeding 100%.
In 2006, a nationally representative seroprevalence study conducted in Cambodia among 
five-year-old children born before vaccine introduction using a rapid point-of-care test found 
a HBsAg seroprevalence of 3.5% (95% Confidence Interval [CI] 2.4–4.8%) [12]. However, 
HBsAg seroprevalence ranged from 8.5% (95% CI 6–11.8%) in least developed provinces 
to 3.2% (95% CI 1.7–5.7%) in most developed provinces. Reasons for the lower HBsAg 
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prevalence in the 2006 study compared with the 9% national HBsAg estimate of the 
Regional Office for the Western Pacific in the general population have not been studied.
To assess the progress of the national immunization program in decreasing the burden of 
disease, we conducted serosurveys in three provinces to ascertain the hepatitis B vaccination 
coverage and HBsAg seroprevalence among children born after the national implementation 
of the hepatitis B vaccination program.
METHODS
In October 2011, we conducted three cross-sectional two-stage cluster surveys among 
children born from January 1, 2006 to December 31, 2007 in Phnom Penh, Kratie, and 
Ratanakiri provinces, which were selected to represent different regions of Cambodia with 
respect to population density (urban/rural/remote) and varying hepatitis B vaccination 
coverage (Figure 1). Phnom Penh is an urban province with urban poor, close quarters, good 
access to healthcare facilities, and 92% BD/90% HepB3 coverage in 2010. Kratie is a rural 
province, with 58% BD/74% HepB3 coverage in 2010. Ratanakiri is a remote sparsely 
populated province with few health facilities, and 47% BD/40% HepB3 coverage in 2010 
[11]. Because of differences in coverage, the survey was designed to estimate province-
specific HBsAg prevalence.
Sample size and sampling
Reported vaccination coverage was used to model expected province-specific HBsAg 
prevalence for sample size calculation [13]. The sample size of 1211 children in Phnom 
Penh, 563 children in Kratie, and 626 children in Ratanakiri was calculated based on the 
expected HBsAg seroprevalence and desired precision of 4.5%±1.5% in Phnom Penh, 5.9%
±2.5% in Kratie, and 6.6 %±2.5% in Ratanakiri with 95% probability. Less precision for the 
rural/remote provinces was considered acceptable considering the difficult field logistics and 
that higher precision would not likely change the outcome and program guidance. The 
design effect for the cluster sampling design was assumed to be 1.5 with a 10% non-
response rate, based on the design effect found in the 2006 national hepatitis B 
seroprevalence study which used a similar sampling design and testing methodology [12].
Sampling within provinces was done in two stages. In the first stage, 40 villages were 
chosen in Phnom Penh, 30 in Kratie, and 40 in Ratanakiri based on probability proportional 
to size sampling methodology. In the second stage, a fixed number of children born during 
2006 and 2007 were selected within each village. In order to find these children, one team 
started in the center, and one team started at the periphery of the village. Each team chose a 
random direction and visited houses sequentially searching for children within the target age 
group until the desired number were enrolled. Only one child was selected in each 
household. In the few instances where a selected village did not have enough children to 
meet the required sample size, the remainder was randomly selected from a neighboring 
village.
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Data Collection
If consent was obtained, a brief questionnaire was administered to the caregiver. The 
questionnaire collected demographic data, potential risk factors for infection and vaccination 
history. If written vaccination history was not available, vaccination history based on 
caregiver recall was obtained.
Specimen Collection and HBsAg Testing
Approximately 50uL of blood was collected from each child by finger prick and was tested 
in the field using the Alere Determine™ HBsAg point-of-care test strip (reported sensitivity: 
95%–100%; reported specificity: 96%–100%) [14–16].
Data management and analysis
The data were double entered and stored in Epidata v3.5.3 (Odense, Denmark). Data were 
analyzed in SAS v9.3 (Cary, NC, USA) and SUDAAN v10 (Research Triangle Park, NC, 
USA). Provinces were analyzed separately; analyses accounted for the two-stage cluster 
design. Wilson CIs are given for proportions that are outside the range of 20%–80%, 
otherwise Wald CIs are reported.
For each province, model-adjusted relative risks were calculated using a multivariable 
logistic model to summarize variables independently associated with not receiving a timely 
BD and not receiving at least three doses of hepatitis B vaccine. We defined “timely BD” as 
a dose of hepatitis B vaccine given within 24 hours of birth. We defined “≤7 day BD” as a 
dose of hepatitis B vaccine given within seven days of birth. The models included all 
variables with epidemiologic plausibility as well as those having a p-value <0.1 on 
individual variable analysis. The adjusted relative risks (aRR) from the three provincial 
models were similar in magnitude and direction for all variables; therefore the data were 
combined into a single overall model.
Human Subjects Rights and Ethics
Informed consent was obtained from the caregivers of all participants. The study protocol 
was approved by the Cambodia National Ethics Committee for Health Research and the 
Ethics Review Committee at the WHO Regional Office for the Western Pacific.
RESULTS
In Phnom Penh, 1240 eligible children were identified, of whom 1199 participated, and 
1196 were analyzed. In Kratie, 570 eligible children were identified, of whom 569 
participated and were analyzed. In Ratanakiri, 640 eligible children were identified, of 
whom 640 participated and 637 were analyzed. Two participating children were found to be 
born outside of the age group targeted and were excluded from analysis; an additional three 
children were excluded from the study analysis because they refused the blood test. One 
child was excluded because the test was done incorrectly and was not able to be repeated.
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Children in the three provinces were different with respect ethnicity, maternal education, 
location of birth and delivery attendant, school attendance, and vaccine card availability 
(Table 1), which reflect the variation in the underlying populations of the three provinces.
Timely BD coverage, ≤7 day coverage, and HepB3 coverage were higher in Phnom Penh 
(55%, 77%, 91%), when compared with Kratie (36%, 53%, 82%), and Ratanakiri (22%, 
30%, 64%) (Table 2).
Caregivers had increased awareness about hepatitis B in Phnom Penh (88%) and Kratie 
(86%), compared with Ratanakiri (61%). Caregivers reported several reasons why their child 
had not received at least three doses of hepatitis B vaccination. Of 198 caregivers in Phnom 
Penh, 39 (20%) reported they were too busy, 26 (13%) reported they did not know where to 
go for vaccination, 24 (12%) were not in the area when vaccine was due, and 21 (11%) 
forgot it was time. Of 147 caregivers in Kratie, 64 (44%) reported being too busy, 41 (28%) 
were not in the area when the vaccine was due, 32 (22%) did not know where to go for 
vaccination, and 26 (18%) forgot it was time. Of 287 caregivers in Ratanakiri, 86 (30%) did 
not know where to go for vaccination, 77 (27%) reported being too busy, 54 (19%) were not 
in the area when the vaccine was due, and 31 (11%) reported thinking vaccination was 
unimportant.
Factors Associated with Under-Vaccination
When compared with children who were born in health facilities with an SBA, children born 
at home without a SBA were more likely not to have received a timely BD (aRR=1.94; 95% 
CI=1.75–2.15) (Table 3). The risk of not receiving a timely BD was also greater among 
children born at home with an SBA when compared with children born in a health facility 
with an SBA (aRR=1.54; 95% CI=1.32–1.80). Children with mothers who had received at 
least a primary or secondary school education were approximately 30% less likely to be 
unvaccinated with a timely BD compared with those with mothers having no schooling 
(Table 3). In the provincial-specific models, Khmer ethnicity was significantly associated 
with the receipt of birth dose only in Kratie (aRR=0.8 95% CI=0.6–0.9); ethnicity was not 
significant when the data were pooled from all three provinces.
A different set of risk and protective factors were seen for under-vaccination with three 
doses of hepatitis B vaccine. A risk factor for under-vaccination was being born at home 
without an SBA (aRR=2.55, 95% CI=1.84–3.55), while being born at home with an SBA 
was not significantly different than being born in a health facility (aRR=1.11; 95% CI=0.78–
1.58). Protective factors included being of Khmer ethnicity, maternal primary or secondary 
education, caregiver knowledge of hepatitis B, and attendance at school by the child (Table 
3).
HBsAg Prevalence and Factors Associated with HBsAg Seropositivity
HBsAg was detected among 4 of 1196 (0.33%, 95% CI 0.1–0.9%) children in Phnom Penh; 
8 of 569 (1.41%, 95% CI 0.6–3.1%) children in Kratie, and 22 of 637 (3.45%, 95% CI 1.9–
6.3%) children in Ratanakiri.
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In all three provinces, children who received their first dose after seven days of life and 
children who never received hepatitis B vaccine had the highest HBsAg prevalence (Table 
4). Two children who received a timely BD were seropositive; one child had received only 
one subsequent dose approximately 10 weeks after BD administration; the other child only 
had caregiver-reported vaccination data provided, so dates of administration are unverified 
and based on recall.
In Phnom Penh, HBsAg prevalence was 0.2% (2/981) among children with vaccination data 
either by card or recall who received ≥3 doses, compared with 2% (2/100) among children 
who received <3 doses (RR=0.1, 95% CI 0.01–0.7). In Kratie, HBsAg prevalence was 1.7% 
(7/418) among children with vaccination data either by card or recall who received ≥3 doses, 
compared with 1.1% (1/93) among children who received <3 doses, (RR=1.6, 95% CI 0.2–
11.6). In Ratanakiri, HBsAg prevalence was 0.9% (3/347) among children with vaccination 
data either by card or recall who received ≥3 doses, compared with 8.6% (17/198) among 
children who received <3 doses (RR=0.1, 95% CI 0.03–0.4).
Discussion
The primary objectives of this evaluation were to assess vaccination coverage and burden of 
chronic HBV infection among vaccine-eligible children in three provinces. HBsAg 
seroprevalence was 0.33% among 4- to 5-year-old children in Phnom Penh, an urban 
province, 1.41% in Kratie, a rural province, and 3.45% in Ratanakiri, a remote province. 
These provincial estimates are considerably lower than the national pre-vaccine HBsAg 
prevalence estimate of 9% [3] and in two provinces were lower than the national prevalence 
estimate of 3.5% reported from the 2006 serosurvey [12]. However, these results cannot 
confirm a decrease in HBsAg prevalence nationally since heterogeneity in HBsAg 
prevalence exists throughout the country. What is notable is that the lowest seroprevalence 
estimates were in those areas with the highest vaccination coverage for timely BD coverage, 
≤7 day BD coverage, and HepB3 coverage. Much room for improvement exists, especially 
with regards to timely BD in all three provinces, as well as 3-dose coverage, especially in 
Ratanakiri. Increasing coverage can prevent further transmission.
We evaluated the impact of the timing of BD administration on the risk of HBsAg 
seropositivity, although this analysis was limited due to the low number of seropositive 
children. Children who did not receive any vaccine or received the first dose after seven 
days of life were more likely to be HBsAg seropositive, which is consistent with other 
published literature [17, 18]. However, we were unable to differentiate the impact of 
receiving a hepatitis B vaccine dose ≤24 hours compared to 2–7 days after birth though the 
study was not powered for this analysis. In China, one study found no difference in 
seroprevalence between children who received a dose within ≤24 hours compared to 2–7 
days, while a second study found that those who received a BD within 2–7 days were three 
times more likely to be HBsAg positive compared to children who received a BD within ≤24 
hours [19, 20]. Further research is needed to guide future policy recommendations on timing 
of the birth dose. This should not preclude countries from striving to achieve high coverage 
of a timely BD as recommended by WHO [21].
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We found that children were approximately two times more likely to miss a timely BD if 
they were born at home without an SBA when compared with children born in health 
facilities. Timely BD for a baby delivered without an SBA at home requires the mother to 
visit a health facility within 24 hours of delivery which can be challenging. Furthermore, in 
the remote province of Ratanakiri, where there are few health facilities that are far apart, the 
risk of not receiving a timely BD is greater. While less likely than home births without an 
SBA, children born at home with an SBA were 1.5 times more likely to not receive a timely 
BD when compared with children born in health facilities. This is an opportunity for 
improving timely BD administration, as all SBAs are trained and able to administer an 
injection. The ability of SBAs to provide timely BD can be strengthened by providing high-
quality training and ensuring that all SBAs have a supply of hepatitis B vaccine.
Concerted efforts have been made in Cambodia to increase facility-based deliveries. 
Hospital deliveries accounted for 22% of all births in 2005 and 54% of all births in 2010; a 
concomitant rise nationally in timely BD coverage has been observed from 25% in 2006 to 
57% in 2010 [10, 11, 22]. Until every child is delivered in a health facility, the Cambodian 
Ministry of Health is attempting to reach infants born at home via outreach services. In other 
countries with a high number of unattended home births, successful strategies, such as the 
use of simple injection devices (e.g. Uniject) and the use of the vaccine in a controlled-
temperature chain have been implemented to reach these infants [23–26].
We found that children born in health facilities were more likely to receive at least three 
doses of hepatitis B vaccine compared with children born at home without an SBA. In 
Indonesia, children delivered by an SBA were more likely to have received measles vaccine; 
in South Africa, children delivered at home were less likely to have received measles 
vaccine [27, 28]. We hypothesize that delivery by an SBA and delivery in a health facility 
could be surrogate markers for increased access to immunization services. Additionally, 
improving facility delivery rates could help improve both BD vaccination coverage and 
coverage for other routine vaccines by providing an opportunity to educate mothers of the 
need for vaccines.
This study had several limitations. First, the rapid test used in this study has a reported 
sensitivity of 95%; therefore the HBsAg prevalence in this study might be lower than the 
true seroprevalence [15]. Vaccination data collected by recall are not as reliable as 
vaccination card data, especially since we asked questions to the parents about an event that 
happened four to five years ago. We assessed only a few risk factors for low vaccine 
coverage and for acquiring chronic HBV infection. Other important factors such as low 
socioeconomic status and household crowding were not assessed [29–33]. Additionally, 
small numbers of HBsAg positive children limited stratification by receiving a birth dose 
and limited evaluation of the impact of ≥3 dose hepatitis B coverage.
Within a decade, high 3-dose hepatitis B vaccination coverage has been achieved as well as 
a steadily improving timely BD coverage. Applying the provincial estimates from this study 
to the proportion of the country’s population living in urban (37%), rural (58%), and remote 
(6%) provinces, and assuming that heterogeneity in baseline seroprevalence and BD and 3-
dose coverage can be explained by this geographical classification, we hypothesize that the 
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WHO Western Pacific Region’s hepatitis B control milestone to reduce chronic HBV 
infection prevalence to <2% in children aged <5 years by 2012 might have been achieved in 
Cambodia.
The Cambodia Ministry of Health along with all other countries in the Western Pacific 
Region has adopted a goal to reduce HBsAg prevalence to <1%. To reach this goal, 
continued improvements in 3-dose hepatitis B vaccination coverage and timely BD coverage 
are needed, especially in rural and remote areas. Improvements can be made in timely BD 
coverage by continuing efforts to increase facility births, by ensuring that national policies 
are implemented in all health facilities to administer a BD to all infants within 24 hours of 
delivery, and for SBAs who attend home deliveries to administer a timely BD vaccine as 
part of newborn care services [34].
Acknowledgments
Funding: This work was supported by the World Health Organization’s Regional Office for the Western Pacific.
The authors wish to thank Theng Van Piseth, Thiep Chanthan, Saphonn Vonthanak, Mey Vannareth and Aim 
Sothea, as well as our field coordinators, supervisors and data collectors for their efforts and commitment to 
facilitate and gather high-quality data. Additionally, we would like to thank the provincial health department 
officers, operational health district officers and families participating in this evaluation.
Abbreviations
aRR adjusted Relative Risk
BD Hepatitis B birth dose
CI Confidence Interval
DE Design Effect
HBsAg hepatitis B surface antigen
HBV Hepatitis B virus
HepB3 3-dose hepatitis B vaccination coverage
ICC Intra-class correlation
RR Relative Risk
SBA Skilled Birth Attendant
WHO World Health Organization
References
1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: 
new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012 Mar 9; 30(12):
2212–9. [PubMed: 22273662] 
2. Clements CJ, Baoping Y, Crouch A, Hipgrave D, Mansoor O, Nelson CB, et al. Progress in the 
control of hepatitis B infection in the Western Pacific Region. Vaccine. 2006 Mar 15; 24(12):1975–
82. [PubMed: 16361001] 
Bunsoth et al. Page 8
Vaccine. Author manuscript; available in PMC 2015 November 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3. World Health Organization Regional Office for the Western Pacific. Western Pacific Regional Plan 
for Hepatitis B Control through Immunization. Manila, Philippines: World Health Organization; 
2007. 
4. Snitbhan R, Scott RM, Bancroft WH, Top FH Jr, Chiewsilp D. Subtypes of hepatitis B surface 
antigen in Southeast Asia. J Infect Dis. 1975 Jun; 131(6):708–11. [PubMed: 48531] 
5. Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P. Prevalence of markers of 
hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. 
Southeast Asian J Trop Med Public Health. 1993 Jun; 24(2):239–49. [PubMed: 7505485] 
6. Ohshige K, Morio S, Mizushima S, Kitamura K, Tajima K, Ito A, et al. Cross-sectional study on risk 
factors of HIV among female commercial sex workers in Cambodia. Epidemiol Infect. 2000 Feb; 
124(1):143–52. [PubMed: 10722142] 
7. PATH. Hep B Sero-Prevalence Study Rural Cambodia, 2001 2001.
8. Ngoan, LT. International epidemiological collaborative surveillance, epidemiology and prevention 
of HBV, HCV, HIV and rabies at the greater Mekong sub-region. Hanoi, Vietnam: Hanoi Medical 
University; 2010. 
9. Ol HS, Bjoerkvoll B, Sothy S, Van Heng Y, Hoel H, Husebekk A, et al. Prevalence of hepatitis B 
and hepatitis C virus infections in potential blood donors in rural Cambodia. Southeast Asian J Trop 
Med Public Health. 2009 Sep; 40(5):963–71. [PubMed: 19842380] 
10. World Health Organization. Immunization Profile - Cambodia. 2011. [cited August 22, 2012]; 
Available from: http://apps.who.int/immunization_monitoring/en/globalsummary/
countryprofileresult.cfm
11. National Institute of Statistics, Directorate General for Health, ICF Macro. Cambodia 
Demographic and Health Survey. Phnom Penh, Cambodia and Calverton, Maryland, USA: 
National Institute of Statistics, Directorate General for Health, and ICF Macro; 2011. 
12. Soeung SC, Rani M, Huong V, Sarath S, Kimly C, Kohei T. Results from nationwide hepatitis B 
serosurvey in Cambodia using simple and rapid laboratory test: implications for National 
Immunization Program. Am J Trop Med Hyg. 2009 Aug; 81(2):252–7. [PubMed: 19635879] 
13. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to 
estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005 Dec; 
34(6):1329–39. [PubMed: 16249217] 
14. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, et al. Evaluation of rapid 
diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B 
surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 2000 Feb; 
62(2):301–9. [PubMed: 10813489] 
15. Alere. Alere Determine HBsAg Package Insert. 2011. http://www.alere.com/EN_ZA/products/
alere-determine-hbsag/.Chiba,Japan
16. World Health Organization. Hepatitis B Surface Antigen Assays: Operational Characteristics 
(Phase 1) Report 1. Geneva: World Health Organization; 2001. 
17. Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, et al. Lombok Hepatitis B Model 
Immunization Project: toward universal infant hepatitis B immunization in Indonesia. J Infect Dis. 
1995 Feb; 171(2):290–6. [PubMed: 7844364] 
18. Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in 
infants of carrier mothers. American journal of epidemiology. 1994 Oct 15; 140(8):734–46. 
[PubMed: 7942775] 
19. Cui F, Li L, Hadler SC, Wang F, Zheng H, Chen Y, et al. Factors associated with effectiveness of 
the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine. 2010 Aug 23; 28(37):5973–8. 
[PubMed: 20637773] 
20. Shen LP, Zhang Y, Wang F, Zhang S, Yang JY, Fang KX, et al. Epidemiological changes in 
hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination 
programme. Epidemiol Infect. 2011 Aug; 139(8):1159–65. [PubMed: 21156099] 
21. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009 Oct 1; 84(40):405–
19. [PubMed: 19817017] 
Bunsoth et al. Page 9
Vaccine. Author manuscript; available in PMC 2015 November 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
22. National Institute of Public Health, National Institute of Statistics [Cambodia] Macro O. Cambodia 
Demographic and Health Survey 2005. Phnom Penh; Cambodia and Calverton, Maryland, USA: 
2006. 
23. Sutanto A, Suarnawa IM, Nelson CM, Stewart T, Soewarso TI. Home delivery of heat-stable 
vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull 
World Health Organ. 1999; 77(2):119–26. [PubMed: 10083709] 
24. Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, et al. At-birth immunisation 
against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. 
Vaccine. 1999 Oct 14; 18(5–6):498–502. [PubMed: 10519939] 
25. Wang L, Li J, Chen H, Li F, Armstrong GL, Nelson C, et al. Hepatitis B vaccination of newborn 
infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull 
World Health Organ. 2007 Sep; 85(9):688–94. [PubMed: 18026625] 
26. Hipgrave DB, Tran TN, Huong VM, Dat DT, Nga NT, Long HT, et al. Immunogenicity of a 
locally produced hepatitis B vaccine with the birth dose stored outside the cold chain in rural 
Vietnam. Am J Trop Med Hyg. 2006 Feb; 74(2):255–60. [PubMed: 16474080] 
27. Fernandez R, Rammohan A, Awofeso N. Correlates of first dose of measles vaccination delivery 
and uptake in Indonesia. Asian Pac J Trop Med. Feb; 4(2):140–5. [PubMed: 21771439] 
28. Coetzee N, Yach D, Blignaut R, Fisher SA. Measles vaccination coverage and its determinants in a 
rapidly growing peri-urban area. S Afr Med J. 1990 Dec 15; 78(12):733–7. [PubMed: 2251631] 
29. Szmuness W. Recent advances in the study of the epidemiology of hepatitis B. The American 
journal of pathology. 1975 Dec; 81(3):629–50. [PubMed: 1108668] 
30. Kruszon-Moran D, McQuillan GM. Seroprevalence of six infectious diseases among adults in the 
United States by race/ethnicity: data from the third national health and nutrition examination 
survey, 1988–94. Advance data. 2005 Mar; 9(352):1–9. [PubMed: 15771149] 
31. Pasquini P, Kahn HA, Pileggi D, Pana A, Terzi J, Guzzanti E. Prevalence of hepatitis B markers in 
Italy. American journal of epidemiology. 1983 Nov; 118(5):699–709. [PubMed: 6637996] 
32. Toukan AU, Sharaiha ZK, Abu-el-Rub OA, Hmoud MK, Dahbour SS, Abu-Hassan H, et al. The 
epidemiology of hepatitis B virus among family members in the Middle East. American journal of 
epidemiology. 1990 Aug; 132(2):220–32. [PubMed: 2372003] 
33. Stuver SO, Boschi-Pinto C, Trichopoulos D. Infection with hepatitis B and C viruses, social class 
and cancer. IARC scientific publications. 1997; (138):319–24. [PubMed: 9353672] 
34. Cambodian Ministry of Health. National Policy on Immunization Programme. Cambodia: 2010. 
35. Bennett S, Woods T, Liyanage WM, Smith DL. A simplified general method for cluster-sample 
surveys of health in developing countries. World health statistics quarterly. Rapport trimestriel de 
statistiques sanitaires mondiales. 1991; 44(3):98–106. [PubMed: 1949887] 
Bunsoth et al. Page 10
Vaccine. Author manuscript; available in PMC 2015 November 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 3-dose hepatitis B vaccination coverage among 1 year-olds by province.a
Provinces selected for the study are noted (PP=Phnom Penh, KR=Kratie, RK=Ratanakiri).
aCambodia 2010 Demographic and Health Survey [11]
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